Roche buys U.S. diagnostics company IQuum in $450 million deal
ZURICH, April 7
ZURICH, April 7 (Reuters) - Swiss drugmaker Roche has agreed to buy privately-held U.S. diagnostics company IQuum in a deal worth up to $450 million to strengthen its molecular diagnostics business.
The Basel-based firm said it will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones.
"With IQuum, we further strengthen our molecular diagnostics offerings with cutting-edge technology and products that serve the point of care segment," said Roland Diggelmann, head of Roche's diagnostics division, in a statement on Monday. (Reporting by Caroline Copley; Editing by Christopher Cushing)
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video